euro-cancer-2018-scientifictracks

7 / 36

Page 51
conferenceseries.com
Volume 10 Journal of Cancer Science & Therapy
ISSN: 1948-5956 Euro Cancer 2018
July 23-25, 2018
July 23-25, 2018 | Rome, Italy
29th Euro-Global Summit on
Cancer Therapy & Radiation Oncology
Combining 2D angiogenesis and 3D osteosarcoma microtissues to improve vascularization
Hassan Chaddad
University of Strasbourg, France
Introduction: The number of patients suffering from cancers worldwide is increasing, and one of the most challenging issues
in oncology continues to be the problem of developing active drugs economically and in a timely manner. Considering the high
cost and time-consuming nature of the clinical development of oncology drugs, better pre-clinical platforms for drug screening
are urgently required. So, there is need for high-throughput drug screening platforms to mimic the in vivo microenvironment.
Angiogenesis is now well known for being involved in tumor progression, aggressiveness, emergence of metastases, and also
resistance to cancer therapies.
Materials & Methods: In this study, to better mimic tumor angiogenesis encountered in vivo, we used 3D culture of
osteosarcoma cells (MG-63) that we deposited on 2D endothelial cells (HUVEC) grown in monolayer. Combination of 2D
HUVEC/3D MG-63 was characterized by indirect immunofluorescence, scanning electron microscopy, optical microscopy
and mRNA expression (qPCR).
Results: We reported that endothelial cells combined with tumor cells were able to form a well-organized network, and those
tubule-like structures corresponding to new vessels infiltrate tumor spheroids. These vessels presented a lumen and expressed
specific markers as CD31 and collagen IV. The combination of 2D endothelial cells and 3D microtissues of tumor cells also
increased expression of angiogenic factors as VEGF, CXCR4 and ICAM1.
Conclusion: The cell environment is the key point to develop tumor vascularization in vitro and to be closer to tumor
encountered in vivo.
Biography
Hassan Chaddad has completed his Pharmacy Degree from Lebanese International University (LIU) and his Masters in Pharmacology from USEK University in Lebanon.
He is now pursuing his PhD from Strasbourg University, Faculty of Medicine (France).
Hassan Chaddad, J Cancer Sci Ther 2018, Volume 10
DOI: 10.4172/1948-5956-C8-144